Recent advances in small molecule prodrugs for cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 3, 2014, Pages 418-439

  Wang, Peng ^a   Jin, Xiao ^b   Cai, Jin ^a   Chen, Junqing ^a   Ji, Min ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anticancer; Cancer; Prodrug; Small molecule; Therapy

Indexed keywords

6 METHOXY 2 METHYL 3 (3, 4, 5 TRIMETHOXYBENZOYL) BENZOFURAN 7 YL PHOSPHATE DISODIUM; ABIRATERONE ACETATE; ALDOXORUBICIN; AMRUBICIN; APAZIQUONE; BANOXANTRONE; BARASERTIB; CANFOSFAMIDE; CAPECITABINE; CEP 9722; COMBRETASTATIN A1 PHOSPHATE; DOXIFLURIDINE; ELACYTARABINE; ETIRINOTECAN PEGOL; FIRTECAN; FLUDARABINE; FLUDARABINE PHOSPHATE; FOSTAMATINIB; GLUFOSFAMIDE; GREEN TEA EXTRACT; IXABEPILONE; IXAZOMIB CITRATE; LAROMUSTINE; N, N' BIS (2 BROMOETHYL) PHOSPHORODIAMIDIC ACID (1 METHYL 2 NITRO 1H IMIDAZOL 5 YL) METHYL ESTER; NELARABINE; PRODRUG; PROMITIL; ROMIDEPSIN; SAPACITABINE; TAMOXIFEN CITRATE; TEMOZOLOMIDE; TOPSALYSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UPAMOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; ASTROCYTOMA; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; BREAST TUMOR; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; IC 50; LYMPHOMA; MESOTHELIOMA; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATE TUMOR; SKIN CANCER; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DOGS; HUMANS; MICE; NEOPLASMS; PRODRUGS; RATS;

EID: 84896728842     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990317     Document Type: Article

References (132)

1. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature, 2005, 438(7070), 967-974.
2. Mann, J. Natural products in cancer chemotherapy: Past, present and future. Nat. Rev. Cancer, 2002, 2(2), 143-148.
3. Hannun, Y.A. Apoptosis and the dilemma of cancer chemotherapy. Blood, 1997, 89(6), 1845-1853.
4. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: Design and clinical applications. Nat. Rev. Drug Discov., 2008, 7(3), 255-270.
5. Stern, L.; Perry, R.; Ofek, P.; Many, A.; Shabat, D.; Satchi-Fainaro, R. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug. Chem., 2009, 20(3), 500-510.
6. Stella, V.; Borchardt, R.; Hageman, M.; Oliyai, R.; Maag, H.; Tilley, J. Prodrugs: Challenges and rewards. Springer: 2007.
7. Rautio, J.; Mannhold, R.; Kubinyi, H.; Folkers, G. Prodrugs and targeted delivery: towards better ADME properties. Wiley-VCH: 2011.
8. Brown, J.M.; Wilson, W.R. Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer, 2004, 4(6), 437-447.
9. Denny, W.A. Prodrug strategies in cancer therapy. Eur. J. Med. Chem., 2001, 36(7-8), 577-595.
10. Singh, Y.; Palombo, M.; Sinko, P.J. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem., 2008, 15(18), 1802-1826.
11. Knox, R.J. Gene-directed enzyme prodrug therapy (GDEPT)--recognizing the present limitations of gene therapy for the treatment of cancer. Curr. Opin. Investig. Drugs, 2001, 2(6), 835-838.
12. Bagshawe, K.D. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Exp. Rev. Anticancer Ther., 2006, 6(10), 1421-1431.
13. O'Brien, S.; Rizzieri, D.A.; Vey, N.; Ravandi, F.; Krug, U.O.; Sekeres, M.A.; Dennis, M.; Venditti, A.; Berry, D.A.; Jacobsen, T.F.; Staudacher, K.; Bergeland, T.; Giles, F.J. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br. J. Haematol., 2012, 158(5), 581-588.
14. Burke, A.C.; Giles, F.J. Elacytarabine-lipid vector technology overcoming drug resistance in acute myeloid leukemia. Exp. Opin. Investig. Drugs, 2011, 20(12), 1707-1715.
15. Kondo, C.; Onuki, R.; Kusuhara, H.; Suzuki, H.; Suzuki, M.; Okudaira, N.; Kojima, M.; Ishiwata, K.; Jonker, J.W.; Sugiyama, Y. Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2). Pharm. Res., 2005, 22(4), 613-618.
16. Garland, L.L.; Taylor, C.; Pilkington, D.L.; Cohen, J.L.; Von Hoff, D.D. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin. Cancer Res., 2006, 12(17), 5182-5189.
17. Thomas, H.D.; Wang, L.Z.; Roche, C.; Bentley, J.; Cheng, Y.; Hardcastle, I.R.; Golding, B.T.; Griffin, R.J.; Curtin, N.J.; Newell, D.R. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. Eur. J. Cancer, 2011, 47(13), 2052-2059.
18. Arpicco, S.; Dosio, F.; Stella, B.; Cattel, L. Anticancer Prodrugs: An Overview of Major Strategies and Recent Developments. Curr. Top. Med. Chem., 2011, 11(18), 2346-2381.
19. Wrasidlo, W.; Gaedicke, G.; Guy, R.K.; Renaud, J.; Pitsinos, E.; Nicolaou, K.C.; Reisfeld, R.A.; Lode, H.N. A novel 2'-(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. Bioconjug. Chem., 2002, 13(5), 1093-1099.
20. Tanino, T.; Nawa, A.; Kondo, E.; Kikkawa, F.; Daikoku, T.; Tsurumi, T.; Luo, C.; Nishiyama, Y.; Takayanagi, Y.; Nishimori, K.; Ichida, S.; Wada, T.; Miki, Y.; Iwaki, M. Paclitaxel-2'-Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity. Pharm. Res., 2007, 24(3), 555-565.
21. Hyatt, J.L.; Tsurkan, L.; Morton, C.L.; Yoon, K.J.; Harel, M.; Brumshtein, B.; Silman, I.; Sussman, J.L.; Wadkins, R.M.; Potter, P.M. Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11. Chem. Biol. Interact., 2005, 157-158, 247-252.
22. Harel, M.; Hyatt, J.L.; Brumshtein, B.; Morton, C.L.; Yoon, K.J.; Wadkins, R.M.; Silman, I.; Sussman, J.L.; Potter, P.M. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action. Mol. Pharmacol., 2005, 67(6), 1874-1881.
23. Lee, S.C.; Chan, W.K.; Lee, T.W.; Lam, W.H.; Wang, X.; Chan, T.H.; Wong, Y.C. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo. Nutr. Cancer, 2008, 60(4), 483-491.
24. Kok, S.H.; Wong, R.S.; Gambari, R.; Cheung, F.; Lam, W.S.; Lau, F.Y.; Cheng, G.Y.; Cheng, C.H.; Lam, K.H.; Chan, S.H.; Tang, J.C.; Chui, C.H.; Ho, K.P. In vitro cytotoxicity of (-)-EGCG octaacetate on MDAMB-231 and SKHep-1 human carcinoma cells: a pharmacological consideration on prodrug design. Int. J. Mol. Med., 2008, 22(6), 841-845.
25. Landis-Piwowar, K.R.; Huo, C.; Chen, D.; Milacic, V.; Shi, G.; Chan, T.H.; Dou, Q.P. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res., 2007, 67(9), 4303-4310.
26. Mishra, B.B.; Tiwari, V.K. Natural products: An evolving role in future drug discovery. Eur. J. Med. Chem., 2011, 46(10), 4769-4807.
27. Kratz, F.; Abu Ajaj, K.; Warnecke, A. Anticancer carrier-linked prodrugs in clinical trials. Exp. Opin. Investig. Drugs, 2007, 16(7), 1037-1058.
28. Xu, Y.M.; Marron, M.T.; Seddon, E.; McLaughlin, S.P.; Ray, D.T.; Whitesell, L.; Gunatilaka, A.A. 2,3-Dihydrowithaferin A-3beta-O-sulfate, a new potential prodrug of withaferin A from aeroponically grown Withania somnifera. Bioorg. Med. Chem., 2009, 17(6), 2210-2214.
29. Mulholland, P.; Ferry, D.; Anderson, D.; Hussain, S.; Young, A.; Cook, J.; Hodgkin, E.; Seymour, L.; Kerr, D. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann. Oncol, 2001, 12(2), 245-248.
30. Hirpara, K.V.; Aggarwal, P.; Mukherjee, A.J.; Joshi, N.; Burman, A.C. Quercetin and its derivatives: Synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anticancer Agents Med. Chem., 2009, 9(2), 138-161.
31. Kim, M.K.; Park, K.; Yeo, W.; Choo, H.; Chong, Y. In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates. Bioorg. Med. Chem., 2009, 17(3), 1164-1171.
32. Russo, M.; Spagnuolo, C; Tedesco, I.; Bilotto, S.; Russo, G.L. The flavonoid quercetin in disease prevention and therapy: Facts and fancies. Biochem. Pharmacol, 2012, 83(1), 6-15.
33. Axarli, I.; Labrou, N.E.; Petrou, C; Rassias, N.; Cordopatis, P.; Clonis, Y.D. Sulphonamide-based bombesin prodrug analogs for glutathione transferase, useful in targeted cancer chemotherapy. Eur. J. Med. Chem., 2009, 44(5), 2009-2016.
34. Yoon, K.J.; Qi, J.; Remack, J.S.; Virga, K.G.; Hatfield, M.J.; Potter, P.M.; Lee, R.E.; Danks, M.K. Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. Mol Cancer Ther., 2006, 5(6), 1577-1584.
35. Stern, L.; Perry, R.; Ofek, P.; Many, A.; Shabat, D.; Satchi-Fainaro, R. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug. Chem., 2009, 20(3), 500-510.
36. Miyoshi, Y.; Iwao, K.; Egawa, C; Noguchi, S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int. J. Cancer, 2001, 92(3), 370-373.
37. Sperker, B.; Werner, U.; Mürdter, T.E.; Tekkaya, C; Fritz, P.; Wacke, R.; Adam, U.; Gerken, M.; Drewelow, B.; Kroemer, H.K. Expression and function of ß-glucuronidase in pancreatic cancer: potential role in drug targeting. Naunyn-Schmiedeberg's Arch. Pharmacol, 2000, 362(2), 110-115.
38. Friedmann, Y.; Vlodavsky, I.; Aingorn, H.; Aviv, A.; Peretz, T.; Pecker, I.; Pappo, O. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma: evidence for its role in colonic tumorigenesis. Am. J. Pathol, 2000, 157(4), 1167-1175.
39. Sperker, B.; Mürdter, T.E.; Schick, M.; Eckhardt, K.; Bosslet, K.; Kroemer, H.K. Interindividual variability in expression and activity of human p-glucuronidase in liver and kidney: consequences for drug metabolism. J. Pharmacol. Exp. Ther., 1997, 281(2), 914-920.
40. Angenault, S.; Thirot, S.; Schmidt, F.; Monneret, C; Pfeiffer, B.; Renard, P. Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy. Bioorg. Med. Chem. Lett, 2003, 13(5), 947-950.
41. Tietze, L.F.; Schuster, H.J.; Krewer, B.; Schuberth, I. Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy. J. Med. Chem., 2009, 52(2), 537-543.
42. Renoux, B.; Legigan, T.; Bensalma, S.; Chadeneau, C; Muller, J.M.; Papot, S. A new cyclopamine glucuronide prodrug with improved kinetics of drug release. Org. Biomol Chem., 2011, 9(24), 8459-8464.
43. Grinda, M.; Clarhaut, J.; Tranoy-Opalinski, I.; Renoux, B.; Monvoisin, A.; Cronier, L.; Papot, S. A heterodimeric glucuronide prodrug for cancer tritherapy: The double role of the chemical amplifier. ChemMedChem, 2011, 6(12), 2137-2141.
44. Prijovich, Z.M.; Leu, Y.L.; Roffler, S.R. Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin. Cancer Chemother. Pharmacol, 2007, 60(1), 7-17.
45. Thomas, M.; Rivault, F.; Tranoy-Opalinski, I.; Roche, J.; Gesson, J.P.; Papot, S. Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy. Bioorg. Med. Chem. Lett., 2007, 17(4), 983-986.
46. Hakimelahi, G.H.; Shia, K.S.; Pasdar, M.; Hakimelahi, S.; Khalafi-Nezhad, A.; Soltani, M.N.; Mei, N.W.; Mei, H.C.; Saboury, A.A.; Rezaei-Tavirani, M.; Moosavi-Movahedi, A.A. Design, synthesis, and biological evaluation of a cephalosporin-monohydroguaiaretic acid prodrug activated by a monoclonal antibody-beta-lactamase conjugate. Bioorg. Med. Chem., 2002, 10(9), 2927-2932.
47. Wang, Y.; Yuan, H.; Wright, S.C.; Wang, H.; Larrick, J.W. Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analog prodrug. BMC Chem. Biol, 2001, 1(1), 4.
48. Phelan, R.M.; Ostermeier, M.; Townsend, C.A. Design and synthesis of a beta-lactamase activated 5-fluorouracil prodrug. Bioorg. Med. Chem. Lett., 2009, 19(4), 1261-1263.
49. Veinberg, G.; Shestakova, I.; Vorona, M.; Kanepe, I.; Domrachova, I.; Lukevics, E. Doxorubicin prodrug on the basis of tert-butyl cephalosporanate sulfones. Bioorg. Med. Chem. Lett., 2004, 14(4), 1007-1010.
50. Bundgaard, H.; Falch, E.; Jensen, E. A novel solution-stable, water-soluble prodrug type for drugs containing a hydroxyl or an NH-acidic group. J. Med. Chem., 1989, 32(12), 2503-2507.
51. Vig, B.; Rautio, J. Amino acid prodrugs for oral delivery: Challenges and opportunities. Ther. Deliv., 2011, 2(8), 959-962.
52. Behrsing, H.P.; Furniss, M.J.; Davis, M.; Tomaszewski, J.E.; Parchment, R.E. In vitro exposure of precision-cut lung slices to 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride (NSC 710305, Phortress) increases inflammatory cytokine content and tissue damage. Toxicol. Sci., 2013, 131(2), 470-479.
53. Hori, K.; Saito, S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumor blood flow stasis. Brit. J. Cancer, 2003, 89(7), 1334-1344.
54. Hori, K. Antineoplastic strategy: Irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). Chemotherapy, 2005, 51(6), 357-360.
55. Lee, J.; Bae, S.; Lee, S.; Choi, H.; Kim, Y.H.; Kim, S.J.; Park, G.T.; Moon, S.K.; Kim, D.H. Discovery of a potent tubulin polymerization inhibitor: Synthesis and evaluation of water-soluble prodrugs of benzophenone analog. Bioorg. Med. Chem. Lett, 2010, 20(21), 6327-6330.
56. Fargnoli, J.; Bhide, R.; Lombardo, L.; Hunt, J.T.; Cai, Z.W.; Barrish, J.; Galbraith, S.; Jeyaseelan, R.; Mortillo, S.; Kukral, D. Preclinical studies of BMS-582664, an alanine prodrug of BMS-540215, a potent, dual inhibitor of VEGFR-2 and FGFR-1 kinases. Proc. Am. Assoc. Cancer Res., 2005, 2005(1), 713.
57. Park, J.W.; Finn, R.S.; Kim, J.S.; Karwal, M.; Li, R.K.; Ismail, F.; Thomas, M.; Harris, R.; Baudelet, C; Walters, I. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res., 2011, 17(7), 1973-1983.
58. Wu, Z.; Shah, A.; Patel, N.; Yuan, X. Development of methotrexate proline prodrug to overcome resistance by MDA-MB-231 cells. Bioorg. Med. Chem. Lett., 2010, 20(17), 5108-5112.
59. Hao, X.K.; Liu, J.Y.; Yue, Q.H.; Wu, G.J.; Bai, Y.J.; Yin, Y. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein. Prostate, 2006, 66(8), 858-866.
60. Wu, W.; Luo, Y.; Sun, C; Liu, Y.; Kuo, P.; Varga, J.; Xiang, R.; Reisfeld, R.; Janda, K.D.; Edgington, T.S.; Liu, C. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res., 2006, 66(2), 970-980.
61. Ravel, D.; Dubois, V.; Quinonero, J.; Meyer-Losic, F.; Delord, J.; Rochaix, P.; Nicolazzi, C; Ribes, F.; Mazerolles, C; Assouly, E.; Vialatte, K.; Hor, I.; Kearsey, J.; Trouet, A. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clin. Cancer Res., 2008, 14(4), 1258-1265.
62. Dubois, V.; Nieder, M.; Collot, F.; Negrouk, A.; Nguyen, T.T.; Gangwar, S.; Reitz, B.; Wattiez, R.; Dasnois, L.; Trouet, A. Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumor-activated prodrug of doxorubicin. Eur. J. Cancer, 2006, 42(17), 3049-3056.
63. Fernandez, A.M.; Van Derpoorten; Dasnois, L.; Lebtahi, K.; Dubois, V.; Lobl, T.J.; Gangwar, S.; Oliyai, C; Lewis, E.R.; Shochat, D. N-Succinyl-(p-alanyl-l-leucyl-l-alanyl-l-leucyl) doxorubicin: An extracellularly tumor-activated prodrug devoid of intravenous acute toxicity. J. Med. Chem., 2001, 44(22), 3750-3753.
64. Shao, L.H.; Liu, S.P.; Hou, J.X.; Zhang, Y.H.; Peng, C.W.; Zhong, Y.J.; Liu, X.; Liu, X.L.; Hong, Y.P.; Firestone, R.A.; Li, Y. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: An experimental study. Cancer, 2012, 118(11), 2986-2996.
65. De Clercq, E. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: The magic of the phosphonate bond. Biochem. Pharmacol., 2011, 82(2), 99-109.
66. Reiser, H.; Wang, J.; Chong, L.; Watkins, W.J.; Ray, A.S.; Shibata, R.; Birkus, G.; Cihlar, T.; Wu, S.; Li, B.; Liu, X.; Henne, I.N.; Wolfgang, G.H.; Desai, M.; Rhodes, G.R.; Fridland, A.; Lee, W.A.; Plunkett, W.; Vail, D.; Thamm, D.H.; Jeraj, R.; Tumas, D.B. GS-9219--a novel acyclic nucleotide analog with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin. Cancer Res., 2008, 14(9), 2824-2832.
67. Morgan, A.S.; Sanderson, P.E.; Borch, R.F.; Tew, K.D.; Niitsu, Y.; Takayama, T.; Von Hoff, D.D.; Izbicka, E.; Mangold, G.; Paul, C.; Broberg, U.; Mannervik, B.; Henner, W.D.; Kauvar, L.M. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res., 1998, 58(12), 2568-2575.
68. Vergote, I.; Finkler, N.; Del Campo, J.; Lohr, A.; Hunter, J.; Matei, D.; Kavanagh, J.; Vermorken, J.B.; Meng, L.; Jones, M. Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or-resistant ovarian cancer. Eur. J. Cancer, 2009, 45(13), 2324-2332.
69. Meng, F.; Evans, J.W.; Bhupathi, D.; Banica, M.; Lan, L.; Lorente, G.; Duan, J.X.; Cai, X.; Mowday, A.M.; Guise, C.P.; Maroz, A.; Anderson, R.F.; Patterson, A.V.; Stachelek, G.C.; Glazer, P.M.; Matteucci, M.D.; Hart, C.P. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol. Cancer Ther., 2012, 11(3), 740-751.
70. Jung, D.; Jiao, H.; Duan, J.X.; Matteucci, M.; Wang, R. Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in rats. Xenobiotica, 2012, 42(4), 372-388.
71. rd. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin. Cancer Res., 2011, 17(9), 2997-3004.
72. Xu, H.; Wang, Z.; Donaldson, J.C.; Yao, H.; Zhou, S.; Kelson, A.B.; Ma, W.; Weber, K.T.; Laborde, E.; Cheng, M.; Sambucetti, L.; Keck, J.G. Antitumor efficacy and molecular mechanism of TLK58747, a novel DNA-alkylating prodrug. Anticancer. Res., 2009, 29(10), 3845-3855.
73. Webster, M.R.; Zhao, M.; Rudek, M.A.; Hann, C.L.; Meyers, C.L. Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells. J. Med. Chem., 2011, 54(19), 6647-6656.
74. Sun, Q.; Li, R.T.; Guo, W.; Cui, J.R.; Cheng, T.M.; Ge, Z.M. Novel class of cyclophosphamide prodrug: Cyclophosphamide spiropiperaziniums (CPSP). Bioorg. Med. Chem. Lett., 2006, 16(14), 3727-3730.
75. Tobias, S.C.; Borch, R.F. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol. Pharm., 2004, 1(2), 112-116.
76. Slusarczyk, M.; McGuigan, C. Application of ProTide technology to gemcitabine: A successful approach to overcome key cancer resistance mechanism. Abstr. Am. Chem. Soc., 2011, 242.
77. Valente, R.; Congiatu, C.; Walsby, E.; Mills, K.; McGuigan, C. MEDI 313-Enhancement of the anticancer activity of cladribine by application of the phosphoramidate protide approach. Abstr. Am. Chem. Soc., 2007, 234.
78. Valente, R.; Congiatu, C.; Walsby, E.; Mills, K.; McGuigan, C. Enhancement of the anticancer activity of cladribine by application of the phosphoramidate protide approach. Abstr. Am. Chem. Soc., 2007, 233, 714-714.
79. Walsby, E.; Congiatu, C.; Schwappach, A.; Walsh, V.; Burnett, A.K.; McGuigan, C.; Mills, K.I. Nucleoside analogs of cladribine produce enhanced responses in cell lines. Blood, 2005, 106(11), 941a-942a.
80. McGuigan, C.; Murziani, P.; Slusarczyk, M.; Gonczy, B.; Vande Voorde, J.; Liekens, S.; Balzarini, J. Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside. J. Med. Chem., 2011, 54(20), 7247-7258.
81. Boyer, S.H.; Sun, Z.L.; Jiang, H.J.; Esterbrook, J.; Gomez-Galeno, J.E.; Craigo, W.; Reddy, K.R.; Ugarkar, B.G.; MacKenna, D.A.; Erion, M.D. Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J. Med. Chem., 2006, 49(26), 7711-7720.
82. Jordheim, L.P.; Dumontet, C. Developments of new compounds and new strategies in the field of cytotoxic nucleoside analogs. Front. Anti-Cancer Drug Discov., 2010, 1, 525-540.
83. Garbaccio, R.M.; Fraley, M.E.; Tasber, E.S.; Olson, C.M.; Hoffman, W.F.; Arrington, K.L.; Torrent, M.; Buser, C.A.; Walsh, E.S.; Hamilton, K.; Schaber, M.D.; Fernandes, C.; Lobell, R.B.; Tao, W.; South, V.J.; Yan, Y.; Kuo, L.C.; Prueksaritanont, T.; Slaughter, D.E.; Shu, C.; Heimbrook, D.C.; Kohl, N.E.; Huber, H.E.; Hartman, G.D. Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility. Bioorg. Med. Chem. Lett., 2006, 16(7), 1780-1783.
84. Boehle, A.S.; Sipos, B.; Kliche, U.; Kalthoff, H.; Dohrmann, P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann. Thorac. Surg., 2001, 71(5), 1657-1665.
85. James, C.; Pettit, G.R.; Nielsen, O.F.; Jayakumar, V.S.; Joe, I.H. Vibrational spectra and ab initio molecular orbital calculations of the novel anti-cancer drug combretastatin A-4 prodrug. Spectrochim Acta A Mol. Biomol. Spectrosc., 2008, 70(5), 1208-1216.
86. Sosa, J.A.; Balkissoon, J.; Lu, S.P.; Langecker, P.; Elisei, R.; Jarzab, B.; Bal, C.S.; Marur, S.; Gramza, A.; Ondrey, F. Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery, 2012, 152(6), 1078-1087.
87. Mooney, C.J.; Nagaiah, G.; Fu, P.; Wasman, J.K.; Cooney, M.M.; Savvides, P.S.; Bokar, J.A.; Dowlati, A.; Wang, D.; Agarwala, S.S.; Flick, S.M.; Hartman, P.H.; Ortiz, J.D.; Lavertu, P.N.; Remick, S.C. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid, 2009, 19(3), 233-240.
88. Hill, S.A.; Toze, G.M.; Pettit, G.R.; Chaplin, D.J. Preclinical evaluation of the antitumor activity of the novel vascular targeting agent Oxi 4503. Anticancer. Res., 2002, 22(3), 1453-1458.
89. Cummings, J.; Zweifel, M.; Smith, N.; Ross, P.; Peters, J.; Rustin, G.; Price, P.; Middleton, M.R.; Ward, T.; Dive, C. Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. Br. J. Cancer, 2012, 106(11), 1766-1771.
90. Patterson, D.M.; Zweifel, M.; Middleton, M.R.; Price, P.M.; Folkes, L.K.; Stratford, M.R.; Ross, P.; Halford, S.; Peters, J.; Balkissoon, J.; Chaplin, D.J.; Padhani, A.R.; Rustin, G.J. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin. Cancer Res., 2012, 18(5), 1415-1425.
91. McAdoo, S.P.; Tam, F.W. Fostamatinib disodium. Drugs Future, 2011, 36(4), 273.
92. Suljagic, M.; Longo, P.G.; Bennardo, S.; Perlas, E.; Leone, G.; Laurenti, L.; Efremov, D.G. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood, 2010, 116(23), 4894-4905.
93. Friedberg, J.W.; Sharman, J.; Sweetenham, J.; Johnston, P.B.; Vose, J.M.; Lacasce, A.; Schaefer-Cutillo, J.; De Vos, S.; Sinha, R.; Leonard, J.P.; Cripe, L.D.; Gregory, S.A.; Sterba, M.P.; Lowe, A.M.; Levy, R.; Shipp, M.A. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood, 2010, 115(13), 2578-2585.
94. London, C.A.; Bear, M.D.; McCleese, J.; Foley, K.P.; Paalangara, R.; Inoue, T.; Ying, W.; Barsoum, J. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS One, 2011, 6(11), e27018.
95. McKeage, M.J.; Gu, Y.; Wilson, W.R.; Hill, A.; Amies, K.; Melink, T.J.; Jameson, M.B. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumor patients. BMC Cancer, 2011, 11, 432.
96. Denny, W.A. Hypoxia-activated prodrugs in cancer therapy: Progress to the clinic. Future Oncol., 2010, 6(3), 419-428.
97. Prasad, A.; Shrivastava, A.; Papadopoulos, E.; Kuzontkoski, P.M.; Reddy, M.V.; Gillum, A.M.; Kumar, R.; Reddy, E.P.; Groopman, J.E. Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma. Clin. Cancer Res., 2013, 19(1), 85-95.
98. Lowenberg, B.; Muus, P.; Ossenkoppele, G.; Rousselot, P.; Cahn, J.Y.; Ifrah, N.; Martinelli, G.; Amadori, S.; Berman, E.; Sonneveld, P.; Jongen-Lavrencic, M.; Rigaudeau, S.; Stockman, P.; Goudie, A.; Faderl, S.; Jabbour, E.; Kantarjian, H. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood, 2011, 118(23), 6030-6036.
99. Zhao, S.; Etzkorn, F.A. A phosphorylated prodrug for the inhibition of Pin1. Bioorg. Med. Chem. Lett., 2007, 17(23), 6615-6618.
100. Okamoto, Y.; Liu, X.; Suzuki, N.; Okamoto, K.; Sekimoto, M.; Laxmi, Y.R.; Shibutani, S. Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate. Int. J. Cancer, 2008, 122(9), 2142-2147.
101. Scicinski, J.; Oronsky, B.; Taylor, M.; Luo, G.; Musick, T.; Marini, J.; Adams, C.M.; Fitch, W.L. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab. Dispos., 2012, 40(9), 1810-1816.
102. McMurtry, V.; Saavedra, J.E.; Nieves-Alicea, R.; Simeone, A.M.; Keefer, L.K.; Tari, A.M. JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. Int. J. Oncol., 2011, 38(4), 963-971.
103. Maciag, A.E.; Chakrapani, H.; Saavedra, J.E.; Morris, N.L.; Holland, R.J.; Kosak, K.M.; Shami, P.J.; Anderson, L.M.; Keefer, L.K. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: Involvement of reactive oxygen species. J. Pharmacol. Exp. Ther., 2011, 336(2), 313-320.
104. Simeone, A.M.; McMurtry, V.; Nieves-Alicea, R.; Saavedra, J.E.; Keefer, L.K.; Johnson, M.M.; Tari, A.M. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res., 2008, 10(3), R44.
105. Edes, K.; Cassidy, P.; Shami, P.J.; Moos, P.J. JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1. PLoS One, 2010, 5(1), e8786.
106. Maciag, A.E.; Saavedra, J.E.; Chakrapani, H. The nitric oxide prodrug JS-K and its structural analogs as cancer therapeutic agents. Anticancer Agents Med Chem, 2009, 9(7), 798-803.
107. Kitagaki, J.; Yang, Y.; Saavedra, J.E.; Colburn, N.H.; Keefer, L.K.; Perantoni, A.O. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53. Oncogene, 2009, 28(4), 619-624.
108. Ji, X.; Pal, A.; Kalathur, R.; Hu, X.; Gu, Y.; Saavedra, J.E.; Buzard, G.S.; Srinivasan, A.; Keefer, L.K.; Singh, S.V. Structure-based design of anticancer prodrug PABA/NO. Drug Des. Devel. Ther., 2008, 2, 123-130.
109. Kumar, V.; Hong, S.Y.; Maciag, A.E.; Saavedra, J.E.; Adamson, D.H.; Prud'Homme, R.K.; Keefer, L.K.; Chakrapani, H. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and double JS-K, through incorporation into PEG-protected nanoparticles. Mol. Pharm., 2009, 7(1), 291-298.
110. Qu, W.; Cheng, L.; Dill, A.L.; Saavedra, J.E.; Hong, S.Y.; Keefer, L.K.; Waalkes, M.P. Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: Requirement for Cyp1a1. Chem. Biol. Interact., 2011, 193(1), 88-96.
111. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7(8), 573-584.
112. Bruijnincx, P.C.A.; Sadler, P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol., 2008, 12(2), 197-206.
113. Wexselblatt, E.; Gibson, D. What do we know about the reduction of Pt(IV) pro-drugs? J. Inorg. Biochem., 2012, 117(0), 220-229.
114. Yang, J.; Sun, X.; Mao, W.; Sui, M.; Tang, J.; Shen, Y. Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy. Mol. Pharm., 2012, 9(10), 2793-2800.
115. Heffern, M.C.; Yamamoto, N.; Holbrook, R.J.; Eckermann, A.L.; Meade, T.J. Cobalt derivatives as promising therapeutic agents. Curr. Opin. Chem. Biol., 2013, 17(2), 189-196.
116. Failes, T.W.; Cullinane, C.; Diakos, C.I.; Yamamoto, N.; Lyons, J.G.; Hambley, T.W. Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug. Chem. Eur. J., 2007, 13(10), 2974-2982.
117. Milbank, J.B.; Stevenson, R.J.; Ware, D.C.; Chang, J.Y.; Tercel, M.; Ahn, G.O.; Wilson, W.R.; Denny, W.A. Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H- pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins. J. Med. Chem., 2009, 52(21), 6822-6834.
118. Parker, L.L.; Lacy, S.M.; Farrugia, L.J.; Evans, C.; Robins, D.J.; O'Hare, C.C.; Hartley, J.A.; Jaffar, M.; Stratford, I.J. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J. Med. Chem., 2004, 47(23), 5683-5689.
119. Bruijnincx, P.C.; Sadler, P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol., 2008, 12(2), 197-206.
120. Zhang, Z.; Hatta, H.; Ito, T.; Nishimoto, S. Synthesis and photochemical properties of photoactivated antitumor prodrugs releasing 5-fluorouracil. Org. Biomol. Chem., 2005, 3(4), 592-596.
121. Lin, W.; Peng, D.; Wang, B.; Long, L.; Guo, C.; Yuan, J. A model for light-triggered porphyrin anticancer prodrugs based on an o-nitrobenzyl photolabile group. Eur. J. Org. Chem., 2008, 2008(5), 793-796.
122. Ibsen, S.; Zahavy, E.; Wrasdilo, W.; Berns, M.; Chan, M.; Esener, S. A novel doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy. Pharm. Res., 2010, 27(9), 1848-1860.
123. Schatzschneider, U. Photoactivated biological activity of transition-metal complexes. Eur. J. Inorg. Chem., 2010, 2010(10), 1451-1467.
124. Hsieh, P.W.; Hung, C.F.; Fang, J.Y. Current prodrug design for drug discovery. Curr. Pharm. Des., 2009, 15(19), 2236-2250.
125. Papadopoulos, K.P.; Goel, S.; Beeram, M.; Wong, A.; Desai, K.; Haigentz, M.; Milian, M.L.; Mani, S.; Tolcher, A.; Lalani, A.S.; Sarantopoulos, J. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin. Cancer Res., 2008, 14(21), 7110-7115.
126. Lalani, A.S.; Alters, S.E.; Wong, A.; Albertella, M.R.; Cleland, J.L.; Henner, W.D. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer. Clin. Cancer Res., 2007, 13(7), 2216-2225.
127. Albertella, M.R.; Loadman, P.M.; Jones, P.H.; Phillips, R.M.; Rampling, R.; Burnet, N.; Alcock, C.; Anthoney, A.; Vjaters, E.; Dunk, C.R.; Harris, P.A.; Wong, A.; Lalani, A.S.; Twelves, C.J. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study. Clin. Cancer Res., 2008, 14(4), 1096-1104.
128. Thorne, S.H.; Barak, Y.; Liang, W.; Bachmann, M.H.; Rao, J.; Contag, C.H.; Matin, A. CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy. Mol. Cancer Ther., 2009, 8(2), 333-341.
129. Heinemann, V.; Ebert, M.P.; Laubender, R.P.; Bevan, P.; Mala, C.; Boeck, S. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br. J. Cancer, 2013, 108(4), 766-770.
130. Pigneux, A. Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy. IDrugs, 2009, 12(1), 39-53.
131. Mittal, S.; Song, X.; Vig, B.S.; Amidon, G.L. Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma. Pharm. Res., 2007, 24(7), 1290-1298.
132. Wang, X.; McKernan, R.; Kim, K.H.; Alvero, A.B.; Whiting, A.; Thompson, J.A.; Mor, G.; Saif, M.W.; Husband, A.J.; Brown, D.M.; Tytler, E.M. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs, 2011, 22(8), 719-731.